TrialAssure adds former Daiichi Sankyo transparency leader to advisory board

TrialAssure named Dr. Oladayo O. Oyelola to its Advisory Leadership Team on June 11, 2026, bringing a veteran disclosure executive to help guide its clinical trial transparency strategy. The appointment comes as sponsors face more global reporting, registration and data-sharing requirements.

Why it matters: - TrialAssure is adding senior in-house expertise as clinical trial transparency rules expand across regions. - Dr. Oladayo O. Oyelola’s background in disclosure operations, regulatory compliance and data sharing could help shape tools sponsors use to meet global obligations. - The move signals growing demand for technology-enabled support as disclosure requirements become more complex.

What happened: - TrialAssure announced the appointment of Oladayo O. Oyelola, PhD, SC (ASCP), to its Advisory Leadership Team on June 11, 2026. - Dr. Oyelola will support TrialAssure’s clinical trial transparency strategy and advise on solutions tied to disclosure, registration, results reporting and data sharing. - The announcement came from TrialAssure, based in Canton, Michigan.

The details: - Dr. Oyelola brings more than 30 years of experience in pharmaceutical research, clinical development, regulatory operations and global clinical trial transparency. - He previously served as Senior Director and Global Head of Clinical Trial Information Disclosure at Daiichi Sankyo. - At Daiichi Sankyo, he led enterprise-wide strategy and operations tied to global transparency and data sharing compliance. - His experience includes disclosure strategies aligned with EMA Policy 0070, Health Canada PRCI, Japan, China and other global mandates. - He has overseen clinical trial registration, results disclosure and data sharing across major portfolios. - His background also includes building policies, processes and training programs for compliant global disclosure operations. - TrialAssure said his perspective will support continued work across technology, services and thought leadership in clinical trial transparency. - Dr. Oyelola said he had been a TrialAssure customer and had seen the company’s approach to practical and responsible transparency solutions. - TrialAssure co-founder and COO Prasad M. Koppolu said Dr. Oyelola has built respect in the clinical trial transparency community through leadership, expertise and commitment to responsible disclosure. - Koppolu said the advisory role will help TrialAssure keep helping the industry move transparency forward. - Dr. Oyelola’s experience also spans medical and technical writing, regulatory submissions and enterprise-level training programs. - TrialAssure’s website is More information.

Between the lines: - Global disclosure expectations are not just increasing; they are also becoming harder to manage consistently across jurisdictions. - Bringing in a former global head of disclosure suggests TrialAssure wants direct operational insight from someone who has handled these requirements at scale. - The appointment also reinforces TrialAssure’s positioning as a vendor focused on practical compliance support rather than software alone.

What’s next: - TrialAssure is expected to use Dr. Oyelola’s experience to refine its transparency strategy and product direction. - The company will likely continue targeting sponsors that need support for disclosure operations across multiple regions. - TrialAssure said it will keep advancing its technology, services and thought leadership in clinical trial transparency and disclosure.

The bottom line: - TrialAssure is betting that deep disclosure expertise will matter more as global transparency rules keep expanding.